YRD had been proven to be effective for the treatment of STC mouse model by restoring the stem cell factor (SCF)/c-kit pathway, increasing interstitial cells of Cajal (ICC) counts and enhancing ICC function [65]. Here, KIT is linked to intrahepatic cholangiocarcinoma.